Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells 3,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the sale, the insider directly owned 106,221 shares of the company’s stock, valued at $12,958,962. This represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Johanna Mercier also recently made the following trade(s):

• On Monday, November 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00.
• On Wednesday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $118.08, for a total value of $354,240.00.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $1.00 during trading on Tuesday, hitting $118.78. 6,211,164 shares of the company were exchanged, compared to its average volume of 7,887,689. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a market cap of $147.37 billion, a price-to-earnings ratio of 18.42, a PEG ratio of 0.67 and a beta of 0.32. The firm’s fifty day moving average price is $122.02 and its 200 day moving average price is $115.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the business earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. UBS Group raised Gilead Sciences to a “hold” rating in a report on Thursday, December 4th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Citigroup increased their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Finally, Scotiabank initiated coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.54.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently modified their holdings of the company. Mirabella Financial Services LLP lifted its stake in shares of Gilead Sciences by 32.7% during the third quarter. Mirabella Financial Services LLP now owns 5,807 shares of the biopharmaceutical company’s stock valued at $643,000 after buying an additional 1,430 shares during the period. Saranac Partners Ltd acquired a new position in Gilead Sciences in the 3rd quarter valued at $118,000. Severin Investments LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at $463,000. Allworth Financial LP lifted its stake in shares of Gilead Sciences by 4.1% during the 3rd quarter. Allworth Financial LP now owns 48,086 shares of the biopharmaceutical company’s stock worth $5,338,000 after purchasing an additional 1,885 shares during the period. Finally, IFP Advisors Inc boosted its holdings in shares of Gilead Sciences by 63.0% during the third quarter. IFP Advisors Inc now owns 10,997 shares of the biopharmaceutical company’s stock worth $1,225,000 after purchasing an additional 4,252 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.